[go: up one dir, main page]

CY1114766T1 - Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας - Google Patents

Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας

Info

Publication number
CY1114766T1
CY1114766T1 CY20141100044T CY141100044T CY1114766T1 CY 1114766 T1 CY1114766 T1 CY 1114766T1 CY 20141100044 T CY20141100044 T CY 20141100044T CY 141100044 T CY141100044 T CY 141100044T CY 1114766 T1 CY1114766 T1 CY 1114766T1
Authority
CY
Cyprus
Prior art keywords
bethanecholis
dry treatment
dry
treatment
ethanol
Prior art date
Application number
CY20141100044T
Other languages
English (en)
Inventor
Nicola Cooper
Julian Clive Gilbert
Robert William Gristwood
Michael Grant Wyllie
Original Assignee
Acacia Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0919822A external-priority patent/GB0919822D0/en
Priority claimed from GBGB1004445.1A external-priority patent/GB201004445D0/en
Application filed by Acacia Pharma Limited filed Critical Acacia Pharma Limited
Publication of CY1114766T1 publication Critical patent/CY1114766T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Μπεθανεχόλη χορηγείται τοπικά, για την αντιμετώπιση ξηροστομίας.
CY20141100044T 2009-11-12 2014-01-17 Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας CY1114766T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0919822A GB0919822D0 (en) 2009-11-12 2009-11-12 The treatment of salivary gland dysfunction
GBGB1004445.1A GB201004445D0 (en) 2010-03-17 2010-03-17 The treatment of salivary gland dysfunction
EP10779033.9A EP2498771B1 (en) 2009-11-12 2010-11-11 Use of bethanechol for treatment of xerostomia

Publications (1)

Publication Number Publication Date
CY1114766T1 true CY1114766T1 (el) 2016-12-14

Family

ID=43382322

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100044T CY1114766T1 (el) 2009-11-12 2014-01-17 Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας

Country Status (23)

Country Link
US (3) US9149454B2 (el)
EP (1) EP2498771B1 (el)
JP (1) JP5595513B2 (el)
KR (1) KR20120092152A (el)
CN (1) CN102711752B (el)
AU (1) AU2010317747B2 (el)
BR (1) BR112012011086A2 (el)
CA (1) CA2780256A1 (el)
CY (1) CY1114766T1 (el)
DK (1) DK2498771T3 (el)
EA (1) EA022040B1 (el)
ES (1) ES2443847T3 (el)
HR (1) HRP20140020T1 (el)
IL (1) IL219613A (el)
MX (1) MX2012005456A (el)
NZ (1) NZ599880A (el)
PL (1) PL2498771T3 (el)
PT (1) PT2498771E (el)
RS (1) RS53124B (el)
SI (1) SI2498771T1 (el)
SM (1) SMT201400008B (el)
WO (1) WO2011058366A1 (el)
ZA (1) ZA201203289B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
AU2016219961B2 (en) 2015-02-18 2020-07-02 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
JP6472722B2 (ja) * 2015-06-30 2019-02-20 サンスター株式会社 口腔内投与する唾液分泌促進剤
WO2017123525A1 (en) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. User interface for diabetes management system
US10835671B2 (en) 2016-01-14 2020-11-17 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
EP3402548B1 (en) 2016-01-14 2025-03-12 Insulet Corporation Occlusion resolution in medication delivery devices, systems, and methods
US10765807B2 (en) 2016-09-23 2020-09-08 Insulet Corporation Fluid delivery device with sensor
EP3500161A4 (en) 2016-12-12 2020-01-08 Bigfoot Biomedical, Inc. ALARMS AND ALERTS FOR MEDICATION DELIVERY DEVICES AND RELATED SYSTEMS AND METHODS
US11033682B2 (en) 2017-01-13 2021-06-15 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
WO2018132754A1 (en) 2017-01-13 2018-07-19 Mazlish Bryan System and method for adjusting insulin delivery
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF ANTIMUSCARINIC AGENT OR ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
CN118750687A (zh) 2018-05-04 2024-10-11 英赛罗公司 基于控制算法的药物输送系统的安全约束
CA3112209C (en) 2018-09-28 2023-08-29 Insulet Corporation Activity mode for artificial pancreas system
WO2020077223A1 (en) 2018-10-11 2020-04-16 Insulet Corporation Event detection for drug delivery system
KR20200083370A (ko) * 2018-12-28 2020-07-08 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
KR20210044714A (ko) 2019-10-15 2021-04-23 인하대학교 산학협력단 노화기인 타액선 기능손상 회복을 위한 혈소판 풍부 혈장 기반 치료 조성물
EP4069082B1 (en) 2019-12-06 2024-06-05 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
EP4088286A1 (en) 2020-01-06 2022-11-16 Insulet Corporation Prediction of meal and/or exercise events based on persistent residuals
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
BR112022016384A2 (pt) 2020-02-18 2022-10-11 Sunstar Americas Inc Composição de cuidado oral
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
EP4185348A1 (en) 2020-07-22 2023-05-31 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US12128215B2 (en) 2020-09-30 2024-10-29 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
US11160925B1 (en) 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
WO2024147928A1 (en) 2023-01-06 2024-07-11 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102340D0 (sv) 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ZA9610154B (en) 1995-12-12 1997-06-17 Universiteit Van Preporia Mouthwash
GB9618341D0 (en) 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
WO1998036733A2 (en) * 1997-02-24 1998-08-27 Michael Albert Kamm Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20070190090A1 (en) * 2006-02-07 2007-08-16 Whitehill Oral Technologies, Inc. Sialagogue based oral care products
JP2010518086A (ja) * 2007-02-09 2010-05-27 デュレクト コーポレーション スフェンタニルおよびナロキソンを含む経口腔投与製剤

Also Published As

Publication number Publication date
AU2010317747A1 (en) 2012-05-31
IL219613A0 (en) 2012-07-31
DK2498771T3 (da) 2014-01-27
SI2498771T1 (sl) 2014-04-30
IL219613A (en) 2016-12-29
US20120232137A1 (en) 2012-09-13
JP2013510840A (ja) 2013-03-28
PT2498771E (pt) 2014-01-30
HRP20140020T1 (hr) 2014-02-14
US9149454B2 (en) 2015-10-06
SMT201400008B (it) 2014-03-07
US10137084B2 (en) 2018-11-27
AU2010317747B2 (en) 2013-10-17
PL2498771T3 (pl) 2014-03-31
CA2780256A1 (en) 2011-05-19
KR20120092152A (ko) 2012-08-20
EA201270619A1 (ru) 2012-12-28
CN102711752A (zh) 2012-10-03
WO2011058366A1 (en) 2011-05-19
EP2498771A1 (en) 2012-09-19
EA022040B1 (ru) 2015-10-30
JP5595513B2 (ja) 2014-09-24
US20160287512A1 (en) 2016-10-06
EP2498771B1 (en) 2013-12-25
ZA201203289B (en) 2013-09-25
BR112012011086A2 (pt) 2016-07-05
US20150366794A1 (en) 2015-12-24
ES2443847T3 (es) 2014-02-20
RS53124B (en) 2014-06-30
NZ599880A (en) 2014-03-28
MX2012005456A (es) 2012-06-19
CN102711752B (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
CY1114766T1 (el) Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας
EA201300730A1 (ru) Производные индазолилтриазола
EA201491009A1 (ru) Гель лизата тромбоцитов
EA201171367A1 (ru) Винилиндазолильные соединения
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
MX2013005994A (es) Monobactamas.
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201100447A1 (ru) Органические соединения
EA201390465A1 (ru) Двойные ингибиторы мэн и фрэс для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
EA201170832A1 (ru) Пуриновые соединения
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2013000308A1 (es) Uso de compuestos heterociclicos con nitrogeno, oxigeno o azufre, para tratar una imperfeccion de la piel tal como una herida superficial, cicatriz o arruga; composiciones farmaceuticas.
MX2011011109A (es) Formulaciones orales de bendamustina.
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
EA201400748A1 (ru) Композиция для обработки семян
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
IN2012DN00539A (el)
EA201201296A1 (ru) Способы лечения диабетических язв стопы
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида